Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
LOC syndrome is a subtype of junctional epidermolysis bullosa (JEB) characterized by an altered cry in the neonatal period and by aberrant production of granulation tissue in particular affecting the upper airway tract, conjunctiva and periungual/subungual sites.
Features include always present findings: Corneal pterygium, Enamel hypoplasia, Hoarse cry, and Nail dystrophy; and sometimes findings: Symblepharon. 9 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 2 | Nail dystrophy, Skin ulcer |
LAMA3 encodes laminin subunit alpha 3 (3,333 aa). Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ext... Highest expression in Lung (30.0 TPM) and Uterus (28.4 TPM).
Laryngo-onycho-cutaneous syndrome is associated with mutations in the LAMA3 gene on chromosome 18.
LAMA3 is classified as a druggable target (Druggable Genome category) with score 1.4.
Genetic testing for LAMA3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 4 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for laryngo-onycho-cutaneous syndrome.
6 publications have been identified in PubMed for laryngo-onycho-cutaneous syndrome. Research spans Case Report / Case Series (33%), Review / Meta-Analysis (17%), and Basic Science / Preclinical (17%).
Ahmad N (2025). [PMID: 41250754](https://pubmed.ncbi.nlm.nih.gov/41250754/). *Respirology case reports*. [Case Report / Case Series]
Goldoni M (2025). [PMID: 39443834](https://pubmed.ncbi.nlm.nih.gov/39443834/). *Pediatric dermatology*. [Gene Therapy / Novel Therapeutics]
Chinchilli E (2025). [PMID: 41048069](https://pubmed.ncbi.nlm.nih.gov/41048069/). *Pediatric dermatology*. [Review / Meta-Analysis]
Suvarnakar A (2025). [PMID: 39420565](https://pubmed.ncbi.nlm.nih.gov/39420565/). *Clinical and experimental dermatology*. [Case Report / Case Series]
Iacoviello M (2025). [PMID: 40806473](https://pubmed.ncbi.nlm.nih.gov/40806473/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 4:11 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Corneal pterygium |
Arms and legs | 1 | Recurrent loss of toenails and fingernails |
Age of onset: newborn period.
Wen D (2024). [PMID: 38157931](https://pubmed.ncbi.nlm.nih.gov/38157931/). *The Journal of investigative dermatology*. [Epidemiology / Natural History]